{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:44:49Z","timestamp":1793897089683,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Institutional Review Board","award":["IRB#00000971"],"award-info":[{"award-number":["IRB#00000971"]}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Psychiatric Association"},{"DOI":"10.13039\/100005386","name":"American Psychiatric Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005386","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Society of Psychopharmacology"},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Health Network Centre for Mental Health"},{"name":"Joseph M. West Family Memorial Fund and Timeposters Fellowship"},{"name":"COMPASS"},{"DOI":"10.13039\/501100003321","name":"Queen's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003321","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre for Neuroscience Studies and Department of Psychiatry"},{"DOI":"10.13039\/100005386","name":"American Psychiatric Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005386","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Society of Biological Psychiatry"},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Institute for Health Research Fellowship Award"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.pnpbp.2020.110126","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T12:16:40Z","timestamp":1601900200000},"page":"110126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence"],"prefix":"10.1016","volume":"105","author":[{"given":"Orly","family":"Lipsitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler S.","family":"Kaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle S.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Brietzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartej","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehala","family":"Subramaniapillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kratiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanna M.W.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Shekotikhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2020.110126_bb0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"Aan Het Rot","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0010","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/da.22501","article-title":"Ketamine\u2019s mechanism of action: a path to rapid-acting antidepressants","volume":"33","author":"Abdallah","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.lfs.2014.02.014","article-title":"The role of mTOR in depression and antidepressant responses","volume":"101","author":"Abelaira","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2016.08.009","article-title":"Ketamine modulates catecholamine transmission in the bed nucleus of stria terminalis: the possible role of this region in the antidepressant effects of ketamine","author":"Cadeddu","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hup.2475","article-title":"The use of ketamine as an antidepressant: a systematic review and meta-analysis","volume":"30","author":"Coyle","year":"2015","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0004867416631828","article-title":"Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation","volume":"51","author":"Cusin","year":"2017","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0035","first-page":"57","article-title":"Inhibition by ketamine of muscarinic acetylcholine receptor function","volume":"81","author":"Durieux","year":"1995","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0040","doi-asserted-by":"crossref","DOI":"10.1176\/ps.2009.60.11.1439","article-title":"What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression","author":"Gaynes","year":"2009","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0045","article-title":"Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment","author":"Godlewska","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0050","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/da.22832","article-title":"Response rate profiles for major depressive disorder: characterizing early response and longitudinal nonresponse","volume":"35","author":"Kelley","year":"2018","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0055","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0060","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0065","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/070674371205701211","article-title":"Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement","volume":"57","author":"Kudlow","year":"2012","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0070","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40263-014-0171-5","article-title":"Early switching strategies in antidepressant non-responders: current evidence and future research directions","volume":"28","author":"Kudlow","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0075","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of \u03b1-Amino-3-Hydroxy-5-Methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0080","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16cs10885","article-title":"Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder","author":"McIntyre","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/bdi.12941","article-title":"The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2020.05.088","article-title":"The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian rapid treatment center of excellence","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0095","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996\u20132013","volume":"65","author":"Mrazek","year":"2014","journal-title":"PS"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/2045125316631267","article-title":"Ketamine enantiomers in the rapid and sustained antidepressant effects","volume":"6","author":"Muller","year":"2016","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0105","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"APA Council of research task force on novel biomarkers and treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbr.2018.07.011","article-title":"Predicting antidepressant response using early changes in cognition: a systematic review","volume":"353","author":"Park","year":"2018","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0115","doi-asserted-by":"crossref","first-page":"112767","DOI":"10.1016\/j.psychres.2020.112767","article-title":"Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder","volume":"284","author":"Park","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0120","doi-asserted-by":"crossref","DOI":"10.1097\/ALN.0000000000000285","article-title":"(R,S)-Ketamine Metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function","author":"Paul","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0130","first-page":"1","article-title":"Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence","author":"Rodrigues","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0135","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18r12475","article-title":"Oral ketamine for depression: a systematic review","volume":"80","author":"Rosenblat","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2018.12.049","article-title":"Impact of subjective vs Objective Remission Status on Subjective Cognitive Impairments in Depression","volume":"246","author":"Sawada","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2013.10.036","article-title":"Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression","volume":"155","author":"Shiroma","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0155","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0160","doi-asserted-by":"crossref","DOI":"10.1055\/s-2007-979551","article-title":"Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses","author":"Stassen","year":"1996","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00023210-199809030-00001","article-title":"Delayed onset of action of antidepressants","volume":"9","author":"Stassen","year":"1998","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0170","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-2007-979192","article-title":"Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement","volume":"32","author":"Stassen","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0175","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v64n0410","article-title":"Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression","author":"Szegedi","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0180","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4088\/JCP.07m03780","article-title":"Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients","volume":"70","author":"Szegedi","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 13","key":"10.1016\/j.pnpbp.2020.110126_bb0185","first-page":"23","article-title":"When at first you don\u2019t succeed: sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12630-017-0833-0","article-title":"How to construct regression models for observational studies (and how NOT to do it!)","volume":"64","author":"Thorpe","year":"2017","journal-title":"Can. J. Anesth."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0195","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1017\/S0033291709991528","article-title":"Trajectories of change in depression severity during treatment with antidepressants","volume":"40","author":"Uher","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0200","article-title":"A neurocognitive model for understanding treatment action in depression","volume":"370","author":"Warren","year":"2015","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0205","doi-asserted-by":"crossref","DOI":"10.1213\/ANE.0b013e3181c95cfa","article-title":"Ketamine inhibits transcription factors activator protein 1 and nuclear factor-\u03baB, Interleukin-8 production, as well as CD11b and CD16 expression: studies in human leukocytes and Leukocytic cell lines","author":"Welters","year":"2010","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/03009734.2012.724118","article-title":"Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test","volume":"118","author":"Yang","year":"2013","journal-title":"Ups. J. Med. Sci."},{"key":"10.1016\/j.pnpbp.2020.110126_bb0220","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0225","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2020.110126_bb0230","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eurpsy.2013.10.005","article-title":"Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex","volume":"29","author":"Zhou","year":"2014","journal-title":"Eur. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620304425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620304425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:52:45Z","timestamp":1759521165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584620304425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":46,"alternative-id":["S0278584620304425"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110126","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110126"}}